Identification of Novel Targetable Kinases in SR-a GvHD

University of Freiburg24 enrolled

Overview

In this study, the investigators aim to identify novel targetable kinases in SR-a GvHD patient samples and investigate their role in different immune cell subtypes.

Corticosteroids are the first-line treatment of a GvHD, however many patients do not respond to corticosteroids. Patients with steroid-refractory a GvHD (SR-a GVHD) have a low 1-year survival rate. In this study, the investigators aim to identify and validate novel targetable kinases in SR-a GvHD patient peripheral blood mononuclear cells (PBMCs) by using a kinase-specific proteomic approach, and thereafter to investigate the role of the identified kinases in different immune cell subtypes by analyzing biopsies taken from SR- a GvHD patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Graft Versus Host Disease

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * allo-transplanted * confirmed diagnosis of a GvHD * age ≥ 18 years * peripheral blood samples and biopsies available * written informed consent * ability to understand the nature of the study and the study-related procedures and to comply with them Exclusion Criteria: * age \< 18 years * lack of informed consent * patients that cannot be classified in one of the 2 groups (steroid-refractory, steroid-responsive)

Outcomes

Primary Outcomes

Identification of differentially regulated kinases

Bead-based Kinase Assay enrichment (Knet beads) of PBMC lysates

Time frame: 3 years

Secondary Outcomes

Analysis of protein expression

Analysis of PBMC lysates by western blot

Time frame: 3 years

Analysis of immune cell subtype

Immunohistochemistry of intestinal biopsies

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.